
Opinion|Videos|March 15, 2024
Efficacy of Zanubrutinib vs Acalabrutinib in R/R CLL: A Matching-Adjusted Indirect Comparison
A comprehensive discussion on a matching-adjusted indirect comparison study investigating the efficacy of zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Ropeginterferon Alfa Gains NCCN Backing in Essential Thrombycythemia
3
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
4
Neoadjuvant Pembrolizumab Achieves High pCR Rates in Desmoplastic Melanoma
5



















